ArticleMolecular therapy. Methods & clinical development2025
Systemic mRNA-LNP administration in fetuses improves survival in a mouse model of spinal muscular atrophy.
Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Base editing provides a unique opportunity for the permanent correction of central nervous system (CNS) diseases with early onset pathology. While lipid nanoparticles (LNPs) have emerged as an effective messenger RNA (mRNA) delivery system for liver base editing, extrahepatic delivery of base editing components to the CNS is poor. To identify CNS-penetrant LNPs, we profiled cell-type-specific mRNA-LNP delivery across developmental stages in the liver and CNS. We identified one LNP (LNP1) with efficient mRNA delivery to endothelial cells, microglia, and neurons in the cortex of fetal recipients. We then applied these findings to spinal muscular atrophy (SMA) and systemically delivered LNP1, encapsulating adenine base editor mRNA and a therapeutic single guide RNA (gRNA) for the upregulation of survival of motor neuron 2 (SMN2) in a humanized severe mouse model of SMA. We demonstrated base editing in the liver and the cortex. Despite low levels of editing in CNS organs, fetal administration modestly increased survival in SMA mice, providing a foundation for a fetal base editing approach for SMA. In conclusion, we leverage our discovery related to basic fetal biology and its influences on mRNA-LNP delivery to develop clinically relevant CNS therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.